Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 2Neoplasms 1

Interventions

pembrolizumab 11Fluorouracil 10Oxaliplatin 8Nivolumab 7Leucovorin 6Cisplatin 6Capecitabine 6Sorafenib 5Ipilimumab 5Cetuximab 5Bevacizumab 5Irinotecan 4trifluridine tipiracil drug combination 3trastuzumab deruxtecan 3durvalumab 3cabozantinib 3Trastuzumab 3Paclitaxel 3zolbetuximab 2trametinib 2sodium thiosulfate 2selpercatinib 2relatlimab 2lenvatinib 2larotrectinib 2encorafenib 2dabrafenib 2binimetinib 2X-Rays 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × lenvatinib × Gastrointestinal × Clear all
NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Phase 3 Completed
954 enrolled 19 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡